N-[2-(dimethylamino)ethyl]-4-propan-2-ylbenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(dimethylamino)ethyl]-4-propan-2-ylbenzenesulfonamide
• 化学式: C₁₃H₂₂N₂O₂S
• 分子量: 270.39
• InChiKey: LUSOUEAECNPUAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：WRASIDLO Wolfgang

  公开号：US20120220584A1

  公开（公告）日：2012-08-30

  Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.

  本文揭示了从苯并三嗪、三嗪、三唑和噁二唑衍生的杂环化合物。还提供了这些杂环化合物的合成和使用方法。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：Hadida Ruah Sara S.

  公开号：US20130296364A1

  公开（公告）日：2013-11-07

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Cha Mi Young

  公开号：US20130116213A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，以及一种药物组合物，其作为活性成分用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导性疾病。
• Heterocyclic compounds as kinase inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11174252B2

  公开（公告）日：2021-11-16

  Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为 CDK4 或 CDK6 或其他 CDK 抑制剂的式 (J) 的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：GIRAFPHARMA LLC

  公开号：US20190248774A1

  公开（公告）日：2019-08-15

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.